UNCY Stock Price | Unicycive Therapeutics Inc P/E, Revenue, EPS, & Forecasts

Unicycive Therapeutics Inc • UNCY

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Unicycive Therapeutics Inc

Ticker

UNCY

Trading on

NASDAQ

ISIN

US90466Y1038

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Shalabh K. Gupta M.D., MPA

Headquarters

1975 West El Camino Real, Mountain View, CA, United States, 94040

Employees

Website

https://unicycive.com

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.

Metrics

BasicAdvanced

Market cap

$212M

P/E ratio

EPS

-$1.67

Dividend Yield

0.00%

Beta

1.77

Forward P/E ratio

3.44

EBIDTA

$-29.5M

Ex dividend date

Price & volume

Market cap

$212M

Average daily volume

0.5M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

3.44

PEG ratio

Trailing P/E

Price to sales

23.75

Price to book

7.01

Earnings

EPS

-$1.67

EPS estimate (current quarter)

-$0.46

EPS estimate (next quarter)

$0.11

EBITDA

$-29.5M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

1.77

52-week High

$11.00

52-week Low

$3.71

50-day moving average

$7.05

200-day moving average

$5.71

Short ratio

3.89

Short %

8.25%

Management effectiveness

ROE (TTM)

-141.15%

ROA (TTM)

-45.66%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

26.7M

Float

22.8M

Insiders %

2.36%

Institutions %

32.88%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 7 analysts.

Average price target

$41.31

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.50

-$0.10

-400.00%

Q1 • 25Missed

-$0.52

-$0.07

-642.86%

Q2 • 25Missed

-$0.33

-$0.07

-398.49%

Q3 • 25Missed

-$0.82

-$0.46

-79.98%

Q4 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-6M

-∞%

Q3 • 25

$0M

$-14.7M

-∞%

Q4 • 25

NaN%

144.00%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$50.6M

$13.1M

25.94%

Q3 • 25

$49.1M

$18.9M

38.54%

Q4 • 25

-2.92%

44.22%

48.56%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-6M

$-0M

$26.3M

$-6M

Q3 • 25

$-8M

$6.6M

$-8M

Q4 • 25

34.72%

-74.91%

34.67%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Unicycive Therapeutics Inc share?

Unicycive Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Unicycive Therapeutics Inc have?

Unicycive Therapeutics Inc currently has 26.7M shares.

Does Unicycive Therapeutics Inc pay dividends?

No, Unicycive Therapeutics Inc doesn't pay dividends.

What is Unicycive Therapeutics Inc 52 week high?

Unicycive Therapeutics Inc 52 week high is $11.00.

What is Unicycive Therapeutics Inc 52 week low?

Unicycive Therapeutics Inc 52 week low is $3.71.

What is the 200-day moving average of Unicycive Therapeutics Inc?

Unicycive Therapeutics Inc 200-day moving average is $5.71.

Who is Unicycive Therapeutics Inc CEO?

The CEO of Unicycive Therapeutics Inc is Dr. Shalabh K. Gupta M.D., MPA.

How many employees Unicycive Therapeutics Inc has?

Unicycive Therapeutics Inc has 21 employees.

What is the market cap of Unicycive Therapeutics Inc?

The market cap of Unicycive Therapeutics Inc is $212M.

What is the P/E of Unicycive Therapeutics Inc?

The current P/E of Unicycive Therapeutics Inc is null.

What is the EPS of Unicycive Therapeutics Inc?

The EPS of Unicycive Therapeutics Inc is -$1.67.

What is the PEG Ratio of Unicycive Therapeutics Inc?

The PEG Ratio of Unicycive Therapeutics Inc is null.

What do analysts say about Unicycive Therapeutics Inc?

According to the analysts Unicycive Therapeutics Inc is considered a buy.